← All trials
NCT05900921
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Jun 13, 2023
- Last posted
- Jun 13, 2023
- Enrollment
- 132
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sichuan UniversityLead sponsor
- Sichuan UniversityCollaborator
- Chengdu Second people's hospitalCollaborator
- Mianyang Central HospitalCollaborator
- Shandong Provincial Cancer HospitalCollaborator
- Shaanxi Provincial People's HospitalCollaborator
- Sichuan UniversityOverall official - principal investigator
- Sichuan UniversityReponsible party - principal investigator
- Sichuan UniversityOfficial
- Sichuan UniversitySponsor investigator
- Shandong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.